[[Image:All_mutations.jpg|200px|right|thumb|Figure 3: Mutations to PPT-1 associated with INCL. Twelve common mutations of INCL are shown in the white on the blue PPT-1 protein.]]
[[Image:All_mutations.jpg|200px|right|thumb|Figure 3: Mutations to PPT-1 associated with INCL. Twelve common mutations of INCL are shown in the white on the blue PPT-1 protein.]]
[https://en.wikipedia.org/wiki/Infantile_neuronal_ceroid_lipofuscinosis Infantile neuronal ceroid lipofuscinosis (INCL)] is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations in PPT-1. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL <ref name="mutations" />.
[https://en.wikipedia.org/wiki/Infantile_neuronal_ceroid_lipofuscinosis Infantile neuronal ceroid lipofuscinosis (INCL)] is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations in PPT-1. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the ''1p32'' chromosome have been identified to cause INCL <ref name="mutations" />.
[[Image:Thr-_mut.png|200px|left|thumb|Figure 4: Common Mutation associated with JNCL and LINCL involve mutations far away from the active Ser-115. ]]
===Mutations leading to Infantile Neuronal Ceroid Lipofuscinosis===
===Mutations leading to Infantile Neuronal Ceroid Lipofuscinosis===
Line 52:
Line 52:
Juvenile NCL (JNCL) and Late-Infantile NCL (LINCL) are less severe forms of INCL in which onset of symptoms occur much later in life; between the ages of 30-40. A possible explanation for the later onset of symptoms could be that the mutations associated with JNCL and LINCL occur away from the active site of PPT-1. Since the mutation does not affect the active site this results in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75, an amino acid located on the alpha-1 helix of PPT-1 (Figure 4). The Thr-75 amino acid is located 20.6Å away from the active site of PPT-1 which indicates that Thr-75 plays no role in the catalytic activity of the catalytic triad
Juvenile NCL (JNCL) and Late-Infantile NCL (LINCL) are less severe forms of INCL in which onset of symptoms occur much later in life; between the ages of 30-40. A possible explanation for the later onset of symptoms could be that the mutations associated with JNCL and LINCL occur away from the active site of PPT-1. Since the mutation does not affect the active site this results in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75, an amino acid located on the alpha-1 helix of PPT-1 (Figure 4). The Thr-75 amino acid is located 20.6Å away from the active site of PPT-1 which indicates that Thr-75 plays no role in the catalytic activity of the catalytic triad
<ref name="mutations" />.
<ref name="mutations" />.
[[Image:Thr-_mut.png|200px|left|thumb|Figure 4: Common Mutation associated with JNCL and LINCL involves mutations far away from the active Ser-115. ]]
In both JNCL and LINCL, the activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way to potentially increase the activity of mutant PPT-1 variants is to use [https://en.wikipedia.org/wiki/Protein_chaperones protein chaperones] that help refold PPT-1 in the [http://en.wikipedia.org/wiki/Endoplasmic_reticulum endoplasmic reticulum]. Although this is not a cure for INCL, increasing the activity of PPT-1 by only '''ABC'''-fold can also increase the life expectancy for individuals with INCL <ref name="Kelly-1">PMID:20346914</ref>.
In both JNCL and LINCL, the activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way to potentially increase the activity of mutant PPT-1 variants is to use [https://en.wikipedia.org/wiki/Protein_chaperones protein chaperones] that help refold PPT-1 in the [http://en.wikipedia.org/wiki/Endoplasmic_reticulum endoplasmic reticulum]. Although this is not a cure for INCL, increasing the activity of PPT-1 by only '''ABC'''-fold can also increase the life expectancy for individuals with INCL <ref name="Kelly-1">PMID:20346914</ref>.
Revision as of 22:24, 24 April 2014
This Sandbox is Reserved from Feb 02, 2011, through Jul 31, 2011 for use by the Biochemistry II class at the Butler University at Indianapolis, IN USA taught by R. Jeremy Johnson. This reservation includes Sandbox Reserved 191 through Sandbox Reserved 200.
To get started:
Click the edit this page tab at the top. Save the page after each step, then edit it again.
Click the 3D button (when editing, above the wikitext box) to insert a 3D applet Jmol scene window.
show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.
Palmitoyl-protein thioesterase 1 (PPT-1) is a small glycoprotein hydrolase found in the lysosome that breaks the thioester bond between cysteine amino acids and palmitic acid[1]. PPT-1 is a homodimer that is composed primarily of alpha helices and beta sheets with a hydrophobic groove that allows the palmitic acid to bind, exposing the thioester bond to the catalytic triad. PPT-1 was first found as an enzyme that removed palmitate from GTPase HRas, in addition to many other cellular substrates [2]. When PPT-1 is not functioning properly, lipid modified proteins can build up in the cells, causing lysosomal storage diseases and aiding in tumor formation [3].
Figure 1: Surface view of PPT-1 (green) showing the hydrophobic groove and palmitate (blue with red oxygen)
Catalytic Triad
The binding surface of PPT-1 creates an external hydrophobic groove that binds the palmitate acid in-between carbon 4 and 5 (Figure 1). The acid binds in a gauche conformation creating a kink
in the acid chain. This bending suggests that PPT-1 was originally designed to react with an unsaturated fatty acid with cis-double bonds. The catalytic triad is composed of Serine-115, Aspartate-233, and Histidine-289 [2]. Ser-115 is deprotonated by His-289 and attacks the carbonyl carbon of the thioester bond connecting palmitic acid to the protein substrate. The negative charge is pushed onto the oxygen and is stabilized by in an oxyanion hole a water molecule. The tetrahedral intermediate collapses and kicks the palmatic acid off of the cysteine residue[2].
File:Simple RXN.pngFigure 2: The basic enzymatic reaction catalyzed by PPT-1. Ser-115, depronated by His-289, attacks the carbonyl carbon of the thioester bond
Inhibitors of PPT-1
PPT-1 is a lysosomal enzyme, which has a serine lipase consensus sequence; a key characteristic of lysosomal enzymes. Despite having a serine lipase consensus sequence, PPT-1, is not deactivated by phenylmethylsulfonyl fluoride (PMSF), a common serine-modifying reagent. Hexadecylsulfonylfluoride (HDSF) is a serine-modifying reagent that is able to bind and inhibit PPT-1. Unlike other inhibitors, HDSF is able to fit in the narrow, hydrophobic groove of PPT-1 leading away from the active site of PPT-1. PMSF is unable to fit into this small narrow groove due to steric constraints that relate to the unique structure of the substrate-binding site of PPT-1. The sulphur of HDSF will bind to SER-115 in the active site of PPT-1 via a sulponylation reaction and thus will inhibit the actions of PPT-1[3].
Disorders Associated With PPT-1
Mutations in Palmitoyl Protein Thioesterase 1 (PPT-1) can cause three types of disorders: Infantile Neuronal Ceroid Lipofuscinosis (INCL), Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL), and Juvenile Neuronal Cerioid Lipofuscinosis (JNCL). The severity of most of the mutations are dependent upon their location inside the protein with respect to the catalytic triad. “Mutations that affect catalysis or substrate binding or disrupt proper folding of the core result in inactive enzymes and lead to a severe clinical phenotype” [2]. Other mutations that cause less severe disorders can sometimes retain some residual thioesterase activity. These less severe mutations are believed to have small, local changes in areas of the protein that are far away from the catalytic triad and palmitate binding site. A more detailed explanation of how some of the different disorders arise through mutations is explained below[2].
Infantile Neuronal Ceroid Lipofuscinosis
Figure 3: Mutations to PPT-1 associated with INCL. Twelve common mutations of INCL are shown in the white on the blue PPT-1 protein.
Infantile neuronal ceroid lipofuscinosis (INCL) is a recessively inherited disease that is associated with a decrease in PPT-1 activity due to mutations in PPT-1. Onset of symptoms which include retinal blindness, ataxia, seizures, and cortical atrophy of the brain, begin 1-2 years after birth. Death typically occurs between the ages of 8-11. Several mutations in the 1p32 chromosome have been identified to cause INCL [2].
Mutations leading to Infantile Neuronal Ceroid Lipofuscinosis
Various mutations have been found in INCL patients[4] . Most of these mutations are caused by nonsense or missense mutations within close proximity to the catalytic triad. These mutations lead to an inactive PPT-1 enzyme as they are predicted to create unfavorable steric, polar, and electrostatic interactions that could disturb the nucleophilic elbow. The nucleophilic elbow is responsible for proper location and orientation of the Ser-115. Catalytic ability would be greatly reduced if the original position of Ser-115 was altered because it must be properly orientated to be activated by His-289 in order to attack the substrate. An example of a JNCL mutation such as Val181Met and Glu184Lys gives a good depiction of how the increase in size in the mutated amino acids and positive charge on lysine mutation would create steric and polar clashes with the adjacent helices of the binding pocket compared to the Normal Val-181 & Glu-184Normal Arg-122 which is described in more detail below.
The most common mutation in INCL that occurs in PPT-1 is a single missense mutation of Arg122Trp. Arg-122 is located immediately after the nucleophilic elbow of PPT-1. The sidechain of Arg-122 has a main function to control the spacing between the αC and α6 helices in this region. This is done by Arg-122 having three hydrogen bonds with three adjacent amino acids: Ile-205, Asn-206, and Gln-205. Mutation of Arg-122 to Trp means not only a loss of those three hydrogen bonds but also a steric and polarity mismatch with the surrounding residues [2]. These Steric Clashes will cause a misfolding of the enzyme’s core and cause it to be trapped in the endoplasmic reticulum, which results in no detectable PPT-1 activity.
Late-Infantile and Juvenile Neuronal Ceroid Lipofuscinosis
Juvenile NCL (JNCL) and Late-Infantile NCL (LINCL) are less severe forms of INCL in which onset of symptoms occur much later in life; between the ages of 30-40. A possible explanation for the later onset of symptoms could be that the mutations associated with JNCL and LINCL occur away from the active site of PPT-1. Since the mutation does not affect the active site this results in a higher activity of the PPT-1 enzyme. A common mutation associated with JNCL and LINCL involves the mutation of Thr-75, an amino acid located on the alpha-1 helix of PPT-1 (Figure 4). The Thr-75 amino acid is located 20.6Å away from the active site of PPT-1 which indicates that Thr-75 plays no role in the catalytic activity of the catalytic triad
[2].
Figure 4: Common Mutation associated with JNCL and LINCL involves mutations far away from the active Ser-115.
In both JNCL and LINCL, the activity of PPT-1 has only a 2% activity rate compared to normal PPT-1 activity. This suggests that a small increase in activity of PPT-1 may aid in delaying the symptoms associated with INCL. One way to potentially increase the activity of mutant PPT-1 variants is to use protein chaperones that help refold PPT-1 in the endoplasmic reticulum. Although this is not a cure for INCL, increasing the activity of PPT-1 by only ABC-fold can also increase the life expectancy for individuals with INCL [5].
Despite the life-threatening diseases associated with decreased PPT-1 activity, inhibition of PPT-1 has also been shown to be a potential cancer target. Proteins involved in signaling and growth are post-translationally modified with palmitic acid. PPT-1 is involved with removing palmitate from lipid-modified proteins and this palmitoylation is necessary for membrane association. When PPT-1 is over expressed, cells become protected from cell death, which leads to tumor formation. PPT-1 inhibition in cultured tumor cells led to selective tumor cell death [5].
Mutations leading to Late-Infantile Neuronal Ceroid Lipofuscinosis
LINCl is caused by a mutation in the CLN2 gene which “codes for a lysosomal pepstatin-insensitive acid protease that is deficient in LINCL patients”[6] . Mutations that tend to lead to LINCL still disrupt the active site and binding pocket geometry, but not to the degree that is seen in INCL. One LINCL mutation is Gln177Glu. Gln-177 acts as a hydrogen bond donor to Ala-171 and Ala-183 and as a hydrogen bond acceptor from Ile-200. The mutation of Gln-177 likely causes a conformation change of the helices in the area. Ala-171 and Ala-183 make hydrophobic contact with the palmitate, and so the altered conformation associated with those two amino acids would decrease binding affinity of the palmitate, decreasing, but not killing the catalytic activity of PPT-1.
Mutations leading to Juvinile Neuronal Ceroid Lipofuscinosis
JNCL is caused by a mutation in the CLN3 gene which codes for a lysosomal membrane protein of unknown function [7]. Unlike the mutations that cause INCL and LINCL, mutations that lead to JNCL are located away from the active site and are seen to cause less damage to the overall structure of PPT-1. Some of the mutations in JNCL have been noted as retaining a low level of PPT-1 activity as the catalytic site is left fairly unperturbed. Mutations associated with JNCl are found in two locations, Thr75Pro with Asp79Gly and Tyr247His with Gly250Val. These mutations are predicted to disturb the geometry of helix α1, increasing the flexibility of the region, and alter the antiparallel βsheet motif in sheets βa and βb compared to the Normal Tyr-247 & Gly-250.
↑Wang R, Borazjani A, Matthews AT, Mangum LC, Edelmann MJ, Ross MK. Identification of palmitoyl protein thioesterase 1 in human THP1 monocytes and macrophages and characterization of unique biochemical activities for this enzyme. Biochemistry. 2013 Oct 29;52(43):7559-74. doi: 10.1021/bi401138s. Epub 2013 Oct, 18. PMID:24083319 doi:https://dx.doi.org/10.1021/bi401138s
↑ 2.02.12.22.32.42.52.62.7Bellizzi JJ 3rd, Widom J, Kemp C, Lu JY, Das AK, Hofmann SL, Clardy J. The crystal structure of palmitoyl protein thioesterase 1 and the molecular basis of infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4573-8. PMID:10781062 doi:10.1073/pnas.080508097
↑ 3.03.1Simonati A, Tessa A, Bernardina BD, Biancheri R, Veneselli E, Tozzi G, Bonsignore M, Grosso S, Piemonte F, Santorelli FM. Variant late infantile neuronal ceroid lipofuscinosis because of CLN1 mutations. Pediatr Neurol. 2009 Apr;40(4):271-6. doi: 10.1016/j.pediatrneurol.2008.10.018. PMID:19302939 doi:https://dx.doi.org/10.1016/j.pediatrneurol.2008.10.018Cite error: Invalid <ref> tag; name "INCL" defined multiple times with different content
↑Hofmann SL, Das AK, Yi W, Lu JY, Wisniewski KE. Genotype-phenotype correlations in neuronal ceroid lipofuscinosis due to palmitoyl-protein thioesterase deficiency. Mol Genet Metab. 1999 Apr;66(4):234-9. PMID:10191107 doi:https://dx.doi.org/10.1006/mgme.1999.2803
↑ 5.05.1Dawson G, Schroeder C, Dawson PE. Palmitoyl:protein thioesterase (PPT1) inhibitors can act as pharmacological chaperones in infantile Batten disease. Biochem Biophys Res Commun. 2010 Apr 23;395(1):66-9. doi:, 10.1016/j.bbrc.2010.03.137. Epub 2010 Mar 25. PMID:20346914 doi:https://dx.doi.org/10.1016/j.bbrc.2010.03.137
↑Vines DJ, Warburton MJ. Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett. 1999 Jan 25;443(2):131-5. PMID:9989590
↑Mitchison HM, Taschner PE, Kremmidiotis G, Callen DF, Doggett NA, Lerner TJ, Janes RB, Wallace BA, Munroe PB, O'Rawe AM, Gardiner RM, Mole SE. Structure of the CLN3 gene and predicted structure, location and function of CLN3 protein. Neuropediatrics. 1997 Feb;28(1):12-4. PMID:9151311 doi:https://dx.doi.org/10.1055/s-2007-973656
